Parmax Pharma Ltd - 540359 - Statement Of Investor Complaints For The Quarter Ended December 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- YASH VORADesignation :- Company Secretary and Compliance Officer Parmax Pharma Ltd - 540359 - Closure of Trading Window
This is to inform you that pursuant to Company's Code of Practices and Procedures and Code of Conduct to Regulate, Monitor and Report Trading in Securities and SEBI (Prohibition of Insider Trading) Regulations, 2015, 'Trading Window' for dealing in securities of the Company will remain closed with effect from 1st January, 2020 till 48 hours after the declaration of financial results for the Quarter and nine months ended 31st December, 2019. Parmax Pharma Ltd - 540359 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
In pursuance to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to kindly intimate you that the Company has received information through its Registrar and Share Transfer Agents i.e. Purva Sharegistry India Private Limited that the following share certificate has been reported as lost or misplaced: Parmax Pharma Ltd - 540359 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
In pursuance to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to kindly intimate you that the Company has received information through its Registrar and Share Transfer Agents i.e. Purva Sharegistry India Private Limited that the following share certificate has been reported as lost or misplaced: Parmax Pharma Ltd - 540359 - Outcome Of The Board Meeting Held On 14Th November, 2019
Dear Sirs, This is to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. 14th November, 2019, inter-alia, considered and approved the Unaudited Financial Results for quarter and half year ended 30th September, 2019. The same has also been reviewed by the Audit Committee in its meeting held today. A copy of the Statement of Unaudited Financial Results for the quarter and half year ended 30th September, 2019, approved by the Board pursuant to Regulation 33 of the Securities And Exchange Board of India (LODR Regulations, 2015, is enclosed for your reference and record. The meeting commenced at 1:00 pm and concluded 5:30 pm. We would like to submit that M/ s. B A Shah S R Mehta & Co., Statutory Auditors of Company have carried out limited review of Unaudited Financial Results for quarter ended and half year ended 30th September, 2019 and Board has also taken on record their Limited Review Report on said Results. Parmax Pharma Ltd - 540359 - The Unaudited Financial Results For Quarter And Half Year Ended 30Th September, 2019
This is to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. 14th November, 2019, inter-alia, considered and approved the Unaudited Financial Results for quarter and half year ended 30th September, 2019. The same has also been reviewed by the Audit Committee in its meeting held today. A copy of the Statement of Unaudited Financial Results for the quarter and half year ended 30th September, 2019, approved by the Board pursuant to Regulation 33 of the Securities And Exchange Board of India (LODR Regulations, 2015, is enclosed for your reference and record. The meeting commenced at 1:00 pm and concluded 5:30 pm. We would like to submit that M/ s. B A Shah S R Mehta & Co., Statutory Auditors of Company have carried out limited review of Unaudited Financial Results for quarter ended and half year ended 30th September, 2019 and Board has also taken on record their Limited Review Report on said Results. Kindly take this on your records. Parmax Pharma Ltd - 540359 - Board Meeting Intimation for Approve The Unaudited Financial Results For The Quarter And Six Months Ended 30Th September, 2019
Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2019 ,inter alia, to consider and approve With reference to the captioned subject, we would like to inform you that the Meeting of the Board of Directors of Parmax Pharma Limited will be held on Thursday, 14th November, 2019 at 01.00 PM at the registered office of the company inter alia to consider, approve the Unaudited Financial Results for the quarter and six months ended 30th September, 2019 and to discuss any other matter with the permission of Board. Parmax Pharma Ltd - 540359 - Shareholding for the Period Ended September 30, 2019
Parmax Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2019. For more details, kindly Click here Parmax Pharma Ltd - 540359 - Certificate Pursuant To Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 30Th September, 2019.
Pursuant to the provisions of Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we are enclosing herewith the certificate received from Mr. Samsad Alam Khan, Practicing Company Secretary, for the half-year ended 30th September, 2019 confirming the compliance of Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This is for your kind information and record please. Parmax Pharma Ltd - 540359 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended 30th September, 2019